

## Supplementary Information

Id2 expression delineates differential checkpoints in the genetic  
program of CD8 $\alpha^+$  and CD103 $^+$  dendritic cell lineages

Jacob T. Jackson<sup>1</sup>, Yifang Hu<sup>2</sup>, Cynthia Liu<sup>2</sup>, Frederick Masson<sup>1</sup>, Angela D'Amico<sup>1</sup>,  
Sebastian Carotta<sup>1</sup>, Annie Xin<sup>1, 3</sup>, Mary J. Camilleri<sup>1</sup>, Adele M. Mount<sup>1</sup>, Axel  
Kallies<sup>1,3</sup>, Li Wu<sup>1,3</sup>, Gordon K. Smyth<sup>2,4</sup>, Stephen L. Nutt<sup>1,3</sup> & Gabrielle T. Belz<sup>1,3</sup>

<sup>1</sup>*Molecular Immunology Division and* <sup>2</sup>*Bioinformatics Division, Walter and Eliza  
Hall Institute of Medical Research, Melbourne, Victoria 3052, Australia;*

<sup>3</sup>*Department of Medical Biology and* <sup>4</sup>*Department of Mathematics and Statistics,  
University of Melbourne, Melbourne, Victoria, 3010.*

Correspondence should be addressed to Gabrielle Belz ([belz@wehi.edu.au](mailto:belz@wehi.edu.au)), The  
Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville,  
Victoria, 3052, Australia. Telephone +61 3 9345 2544; Fax +61 3 9347 0852.

Supplementary Table: 1

Supplementary Figures: 6

## Supplementary Table

Supplementary Table I. Comparative relationship between *in vivo* and *in vitro* DC subsets and sorting regime

Group	DC Subset	<i>In Vivo</i>	<i>In Vitro</i>
1	Bone marrow progenitor	Not sorted <i>in vivo</i>	CD11c <sup>+</sup> /CD103 <sup>-</sup> /Id2-GFP <sup>-</sup> /CD45RA <sup>-</sup>
2	Immature pDC	Not sorted <i>in vivo</i>	CD11c <sup>+</sup> CD103 <sup>-</sup> Id2-GFP <sup>-</sup> CD45RA <sup>int</sup>
3	Mature pDC	CD11c <sup>+</sup> CD45RA <sup>high</sup>	CD11c <sup>+</sup> CD103 <sup>-</sup> Id2-GFP <sup>-</sup> CD45RA <sup>hi</sup>
4	CD8α <sup>+</sup> DC	CD11c <sup>+</sup> CD103 <sup>-</sup> CD8 <sup>+</sup> CD205 <sup>int</sup> (LN) CD11c <sup>+</sup> CD45RA <sup>-</sup> CD4 <sup>-</sup> CD8α <sup>+</sup> (spleen)	CD11c <sup>+</sup> CD103 <sup>-</sup> Id2- GFP <sup>+</sup> CD45RA <sup>int</sup> Sirp-α <sup>-</sup>
5	CD4 DCs	CD11c <sup>+</sup> CD45RA <sup>-</sup> CD8 <sup>-</sup> CD4 <sup>+</sup>	CD11c <sup>+</sup> CD103 <sup>-</sup> Id2- GFP <sup>+</sup> CD45RA <sup>-</sup> Sirp-α <sup>+</sup>
	DN DCs	DN DC Id2-GFP <sup>int</sup> : CD11c <sup>+</sup> CD45RA <sup>-</sup> CD4 <sup>-</sup> CD8 <sup>-</sup> Id2-GFP <sup>int</sup> DN DC Id2-GFP <sup>high</sup> : CD11c <sup>+</sup> CD45RA <sup>-</sup> CD4 <sup>-</sup> CD8 <sup>-</sup> Id2-GFP <sup>high</sup>	
	Langerhans cells	CD11c <sup>+</sup> CD103 <sup>-</sup> CD8 <sup>-</sup> Id2- GFP <sup>high</sup> CD205 <sup>high</sup>	
	Dermal DCs	CD11c <sup>+</sup> CD103 <sup>-</sup> CD8 <sup>-</sup> Id2- GFP <sup>high</sup> CD205 <sup>int</sup>	
6	CD103 DC	CD11c <sup>+</sup> CD8 <sup>-</sup> Id2-GFP <sup>high</sup> CD103 <sup>high</sup>	CD11c <sup>+</sup> CD103 <sup>+</sup> Id2-GFP <sup>high</sup>

**Supplementary Figures**

**Supplementary Figure 1.** Expression of Id2-GFP in pDCs. Dot plots show the analysis of pDCs in indicated tissues. DCs from *Id2<sup>gfp/gfp</sup>* (green line) and wild-type (black line) mice were enriched from (A) thymus, (B) spleen, (C) peripheral LNs and (D) mesenteric LNs and stained with antibodies against surface markers as described in Experimental Procedures. cDCs were identified by their high expression of CD11c and absence of CD45RA while pDCs were identified by their intermediate expression of CD11c and CD45RA. Data show representative profiles and gating strategy for total live cells enriched from lymphoid tissues. Each experiment was performed two to five times with similar results.

**Supplementary Figure 2.** Specificity controls for CD103 expression in *in vitro* DC subsets. Bone marrow cells were isolated from femurs of C57BL/6 and *Itgae<sup>-/-</sup>* (CD103-deficient) mice. Single cell suspensions were depleted of red blood cells then cells were cultured at a density of  $1.5 \times 10^6$  cells/ml in the presence of 100 ng/ml recombinant Flt3L for 5 days. Cells were stained with mAb recognizing CD11c, CD45RA and biotinylated anti-CD103 or anti-Armenian Hamster IgG followed by SA-APC/Cy7. Antibodies recognizing CD3 $\epsilon$ , CD19 and NK1.1 were used to exclude non-DC lineages. Samples were analyzed by flow cytometry and dead cells were excluded by staining with propidium iodide. Profiles are gated on CD11c<sup>+</sup> cells and are representative of at 3 similar experiments (n=7 per group).

**Supplementary Figure 3.** *In vitro* DC subsets have distinct differentiation characteristics. (A) *In vitro* generated *Id2<sup>gfp/gfp</sup>* DCs were fractionated into 6 populations (as shown in Figure 4A) by FACs sorting on day five of culture. (B) Cells


were then re-cultured for a further three days in Flt3L-conditioned medium (recovered from the same cells on day five), then stained for CD11c, CD45RA, CD103 and Sirp- $\alpha$  and analyzed by flow cytometry to determine the survival and phenotype of the differentiated cells. Data are representative of three similar experiments.

**Supplementary Figure 4.** Immature pDCs exhibit similar activation behaviour to mature pDCs *in vitro*. Bone marrow cells from *Id2<sup>gfp/gfp</sup>* mice were cultured at a density of  $1.5 \times 10^6$  cells/ml in the presence of 100 ng/ml recombinant Flt3L for 5 days. Cultures were then stimulated with 1  $\mu$ g/ml LPS, 25  $\mu$ g/ml poly I:C or 500 ng/ml CpG for 18h then stained with mAb recognizing CD11c, CD45RA, Sirp- $\alpha$  and CD103 and CD80 (16-10A1) or MHC class II (M5/114) to monitor activation status. NK cells, B cells and T cells were excluded using negative against anti-NK1.1, anti-CD19 and anti-CD3 $\epsilon$  mAbs. Data are representative of at least three experiments with similar results.


**Supplementary Figure 5.** *In vitro* cross-presentation in Flt3L-stimulated cultures is limited to CD103-expressing *Id2*-GFP<sup>high</sup> DCs. *In vitro* generated *Id2<sup>gfp/gfp</sup>* DCs were flow cytometrically sorted eight days after initiation of cell culture according to their expression of CD103, CD45RA, Sirp- $\alpha$  and *Id2*-GFP and analyzed for their ability to cross-present cell-associated OVA to CFSE-labeled OVA-specific CD8<sup>+</sup> T cells (upper panels). The ability of these subsets of present exogenous antigen to CFSE-labeled OVA-specific CD4<sup>+</sup> T cells was evaluated as a control (lower panels). Data are representative of four independent experiments. T cell proliferation was analysed in 1-3 replicates for each DC subset/responder population for each experiment.

**Supplementary Figure 6.** Analysis of DC subsets in  $Id2^{gfp/gfp}$ ,  $Id2^{gfp/gfp} \times Batf3^{-/-}$  and  $Id2^{gfp/gfp} \times Irf-8^{-/-}$  mice. DCs were enriched from spleen and peripheral LNs from  $Id2^{gfp/gfp}$ ,  $Id2^{gfp/gfp} \times Batf3^{-/-}$  and  $Id2^{gfp/gfp} \times Irf-8^{-/-}$  strains then stained with antibodies against CD11c, CD4, CD45RA, CD8 $\alpha$  or CD103, as described in the Materials and Methods. Samples were analyzed by flow cytometry and dead cells were excluded by staining with propidium iodide. Spleen and LNs were pooled from two to three mice in each group. Dot plots are gated on total CD11c<sup>+</sup> cells showing pDCs (Id2<sup>-</sup>) and cDCs (Id2<sup>+</sup>). Percent and Id2-GFP MFI of CD8 $\alpha$ <sup>+</sup> or CD103<sup>+</sup> cells are shown. Histograms are gated on CD11c<sup>+</sup> cDCs and CD8 $\alpha$  MFI of gated cells are shown (grey,  $Id2^{gfp/gfp}$ ; red,  $Id2^{gfp/gfp} \times Batf3^{-/-}$ ;  $Id2^{gfp/gfp} \times Irf-8^{-/-}$ , blue). Data are representative of at least two to four similar experiments.

# Supplementary Figure 1





Supplementary Figure 2




Supplementary Figure 3


**A** Total Day 5 Flt3L-derived DCs




**B** Population 1. CD103<sup>-</sup>Id2-GFP<sup>-</sup>CD45RA<sup>-</sup>Sirpα<sup>-</sup> (bone marrow precursors)




Population 2. CD103<sup>-</sup>Id2-GFP<sup>-</sup>CD45RA<sup>int</sup> (precursor pDC)




Population 3. CD103<sup>-</sup>Id2-GFP<sup>-</sup>CD45RA<sup>high</sup> (mature pDC)




Population 4. CD103<sup>-</sup>Id2-GFP<sup>+</sup>CD45RA<sup>-</sup>Sirpα<sup>+</sup>



Population 5. CD103<sup>-</sup>Id2-GFP<sup>+</sup>CD45RA<sup>int</sup>Sirpα<sup>-</sup> (CD8α DC precursor)




Population 6. CD103<sup>+</sup>Id2-GFP<sup>+</sup>CD45RA<sup>-</sup>Sirpα<sup>-</sup>






Supplementary Figure 4



Supplementary Figure 5

Day 8



Supplementary Figure 6

